Purchase Order 36C24723P0982
- Not listed
- This federal contract award to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices, is for the provision of its Optune Plus Tumor Treating Fields (TTFields) therapy devices, transducer arrays, rental equipment, and associated support services to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract, valued at $16,582.91, is a delivery order issued under Novocure's 5-year Federal Supply Schedule (FSS) contract with the VA VHA, which...
- This federal contract award, valued at $99,497.46, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices. The contract is a delivery order under a larger 5-year Federal Supply Schedule (FSS) contract (ID: 36F79723D0016) with a $28.85 million ceiling, which the VA VHA awarded to Novocure in November 2022. The contract is for the provision of Novocure's Optune line of Tumor...
- This is a federal contract award to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices, by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract, a Delivery Order under a larger Federal Supply Schedule (FSS) contract with a ceiling value of $28.85 million, is for the provision of Novocure's Optune Plus transducers, device rentals, and related support services. The specific award has a ceiling value of $16,582.91 and a term...
- This federal contract award is to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices, to provide its Optune line of Tumor Treating Fields (TTFields) therapy products and associated support services to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract, a delivery order under a 5-year Federal Supply Schedule (FSS) contract (ID: 36F79723D0016) with a ceiling value of $28.85 million, has a ceiling value of $49,748.73 and a...
- This federal contract award, valued at $96,165.82, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices specializing in cancer therapy. The contract is for the provision of Novocure's Optune line of Tumor Treating Fields (TTFields) therapy devices, transducer arrays, rental equipment, and associated support services for a 6-month period. The contract is a firm fixed-price...
- This federal contract award to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) under a 5-year Federal Supply Schedule (FSS) contract (ID: 36F79723D0016). The contract, valued at a ceiling of $28.85 million, provides the VA with a streamlined procurement vehicle to obtain Novocure's Optune line of Tumor Treating Fields (TTFields) therapy products and services, including...
- This federal contract award, valued at $49,748.73, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 2 (VISN 2) to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices. The contract is for the provision of Novocure's Optune line of Tumor Treating Fields (TTFields) therapy devices, transducer arrays, rental equipment, and associated support services. This contract does not utilize any set-aside designations and is being...
- This federal contract award, valued at $16,582.91, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices. The contract is a delivery order under Novocure's 5-year Federal Supply Schedule (FSS) contract (ID: 36F79723D0016) with the VA VHA, which has a total ceiling value of $28.85 million. The award is for the provision of Novocure's Optune line of Tumor Treating Fields...
- This federal contract award to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract, valued at $16,582.91, is a delivery order under Novocure's 5-year Federal Supply Schedule (FSS) contract with the VA VHA, which has a ceiling value of $28.85 million. The award is for the provision of Novocure's Optune Plus transducers, device rentals, and related support...
- This federal contract award to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices, is a delivery order issued under a $28.85 million Federal Supply Schedule (FSS) contract with the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract, valued at $49,748.73, is for the provision of Novocure's Optune transducers, device rentals, and related support services for the treatment of glioblastoma and mesothelioma at various VA medical centers...
This federal contract award, valued at $99,497.46, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Novocure Inc., a foreign-owned, for-profit manufacturer of medical devices. The contract is for the provision of Novocure's Optune line of Tumor Treating Fields (TTFields) therapy devices, transducer arrays, rental equipment, and associated support services. This award is a delivery order under Novocure's 5-year Federal Supply Schedule (FSS) contract (ID: 36F79723D0016) with the VA VHA, which has a ceiling value of $28.85 million. The contract does not utilize any set-aside designations. Novocure acts as the prime contractor and delivers its proprietary cancer treatment technologies directly to various VA medical centers across the country, including in Portsmouth, New Hampshire; San Antonio, Texas; and Des Moines, Iowa. This contract supports the VA's mission of expanding veterans' access to innovative cancer therapies by enabling VA facilities to offer Novocure's non-invasive TTFields treatment option to veteran patients diagnosed with glioblastoma, mesothelioma, and other solid tumor cancers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $99.5k | 6/6/23 |